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Objective:   SCN8A encephalopathy is a Developmental and Epileptic Encephalopathy (DEE) 
caused by de novo, gain-of-function mutations of sodium channel Nav1.6 that result in neuronal 
hyperactivity.   Affected individuals exhibit early-onset drug-resistant seizures, developmental 
delay and cognitive impairment.  This study was carried out to determine whether reducing the 
abundance of the Scn8a transcript with an anti-sense oligonucleotide (ASO) would delay seizure 
onset and prolong survival in a mouse model of SCN8A encephalopathy. 
Methods:  ASO treatment was tested in a conditional mouse model with Cre-dependent 
expression of the pathogenic patient SCN8A mutation p.Arg1872Trp (R1872W).  This model 
exhibits early onset of seizures, rapid progression and 100% penetrance.  An Scn1a+/- 
haploinsufficient mouse model of Dravet Syndrome was also treated.  ASO was administered by 
intracerebroventricular injection at postnatal day 2, followed in some cases by stereotactic 
injection at postnatal day 30.   
Results: We observed a dose-dependent increase in length of survival from 15 days to 65 days in  
the Scn8a-R1872W/+ mice treated with ASO.  EEG recordings were normal prior to seizure 
onset.  Weight gain and activity in an open field were unaffected, but treated mice were less 
active in a wheel running assay.  A single treatment with Scn8a ASO extended survival of Dravet 
Syndrome mice from 3 weeks to more than 5 months.   
Interpretation:  Reduction of Scn8a transcript by 25 to 50% delayed seizure onset and lethality 
in mouse models of SCN8A encephalopathy and Dravet Syndrome.   Reduction of SCN8A 
transcript is a promising approach to treatment of intractable childhood epilepsies.   
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INTRODUCTION 
 Developmental and epileptic encephalopathies (DEEs) are devastating early-onset 
disorders characterized by seizures and developmental delay (1,2).   Monogenic causes have 
been identified for approximately one third of cases, with voltage-gated neuronal sodium 
channels accounting for 2% of the total (3-5).  SCN8A encephalopathy (MIM#614588) is a DEE 
caused by de novo missense mutations in the SCN8A gene that encodes the neuronal sodium 
channel Nav1.6 (6,7).  Affected individuals are heterozygous for missense mutations that alter the 
biophysical properties of the channel, resulting in premature channel opening, delayed channel 
inactivation, and elevated persistent current (6,8).  Since Nav1.6 has a major role in excitatory 
neurons, elevated activity leads directly to increased neuronal excitability (6).   
 The average age of seizure onset in individuals with SCN8A encephalopathy is 4 months.  
The clinical course is severe, and approximately 50% of affected individuals remain 
nonambulatory and nonverbal.  Long-term seizure control is rarely achieved with anti-epileptic 
drugs (7).  We and others have studied recurrent patient mutations at arginine codon 1872.  
Substitution of arginine 1872 by the uncharged amino acids leucine, glutamine or tryptophan 
impairs inactivation of the Nav1.6 channel (8,9).  We generated a conditional mouse model of 
p.Arg1872Trp that recapitulates the early seizure onset and susceptibility to premature death 
that are characteristic of DEE (10).  
 Since the pathogenic mechanism of SCN8A encephalopathy is neuronal hyperexcitability 
due to gain-of-function mutations, reduction of transcript abundance is a logical therapeutic 
strategy.   Antisense oligonucleotides (ASOs) hybridize by Watson-Crick base-pairing to mRNAs, 
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leading to degradation by RNaseH, inhibition of translation, or altered splicing.  Dominant 
disorders can be treated with allele-specific ASOs that specifically target the mutant transcript, 
or with non-allele-specific ASOs that reduce both mutant and wildtype transcript (11, 12).   The 
application of ASO therapy to neurological disorders is receiving increasing attention (13-15), 
and the FDA has recently approved treatment for Spinal Muscular Atrophy that uses intrathecal 
administration of an ASO at 6 month intervals (16). The goal of the current work is to evaluate 
ASO therapy for SCN8A encephalopathy.  The results provide proof-of-principle that reduction of 
Scn8a transcript can reduce the severity of this devastating disorder  as well as Dravet 
Syndrome, a DEE caused by haploinsufficiency of SCN1A.   
 
METHODS 
Mutant Mice.  The conditional allele of Scn8a (Scn8acond) on background strain C57BL/6J is 
activated by Cre recombinase to express the patient mutation R1872W (10).  The EIIA-Cre 
transgene on background strain C57BL/6J (JAX 003724) is expressed globally in preimplantation 
embryos and in mature oocytes. Homozygous male Scn8a cond/cond mice were crossed with female 
EIIA-Cre mice to generate 50% affected animals (Scn8acond/+,EIIA-Cre) and 50% unaffected 
Scn8acond/+ controls lacking Cre.  Entire litters were randomly assigned to treatment with Scn8a 
or control ASO.  Female EIIA-Cre mice were used for breeding to avoid the mosaic Cre expression 
observed in offspring of male EIIA-Cre mice (10).  The Scn1a model of Dravet Syndrome carries a 
deletion of exon 1 that is maintained in heterozygous state in strain 129S6/SvEvTac (25).  
Experiments were carried out on affected F1 mice generated by crossing with strain C57BL/6J 
This article is protected by copyright. All rights reserved.
 6 
(27).  Mice were housed and cared for in accordance with NIH guidelines in a 12/12h light/dark 
cycle with standard mouse chow and water available ad libitum.  Experiments were approved by 
the Committee on the Use and Care of Animals at the University of Michigan.   Open field activity 
and wheel running were assayed in the Michigan Mouse Metabolic Phenotyping Center (NIH 
U2CDK110768). 
Antisense Oligonucleotides. ASOs were synthesized by Ionis Pharmaceuticals as described 
(28). The ASOs are 20 bp 'gapmers' with five 2′-O-methoxyethyl-modified nucleotides at each 
end and 10 DNA nucleotides in the center.  The Scn8a ASO 5' GACGA TTAGT GACAT AGGCT 3' is 
complementary to the 3' UTR that does not differ between wildtype and mutant transcript 
(Figure 1A).  The control ASO 5' CCTAT AGGAC TATCC AGGAA 3' does not match any transcript 
encoded by the mouse genome and was shown to be well tolerated in the mouse (28).  
Intracerebroventricular (ICV) administration of ASOs.   At postnatal day 2, mice received 2 ul 
of ASO in PBS injected manually into the cerebral ventricle (29). Adult mice received 2.5 ul of 
ASO in PBS by stereotaxic injection into the left ventricle using an automated injector pump 
(Stoetling) connected to a 5-µl Hamilton syringe (30).  Coordinates for stereotaxic injection into 
the cerebral ventricle were M/L=1.0 mm, A/P = 0.3 mm, V/L=3.0 mm. 
qRT-PCR.  Scn8a transcripts in mouse brain and cultured neurons were quantified using TaqMan 
gene expression assays (10). Total Scn8a transcript was detected with the FAM-labelled assay 
Mm00488110_m1 using as endogenous control the Tata binding protein mRNA (VIC labelled 
Mm01277042_m1).  Relative transcript quantity was calculated by the ∆∆CT method (31). Data 
represent the average result from two independent cDNA preparations for each animal.    
This article is protected by copyright. All rights reserved.
 7 
Western blotting.   Purified membrane protein was prepared from whole brain and analyzed by 
Western blotting essentially as described (33). The primary antibodies were rabbit anti-Nav1.6 
(Millipore #5580, lot 3188705) diluted 1:500, and mouse anti-tubulin (Millipore # MAB 1637 lot 
2080833) diluted 1:1,000. 
 
RESULTS  
 The Scn8a ASO targets a sequence in the proximal 3' UTR of mouse Scn8a (Figure 1A).  
Addition of ASO to the culture medium of wildtype primary mouse neurons generates a dose-
dependent reduction in transcript abundance (Figure 1B).  Wildtype mice of strain C57BL/6J 
were treated on postnatal day 2 (P2) by intracerebroventricular (ICV) injection of ASO, and the 
abundance of Scn8a transcript in brain RNA was measured at P21.  Control ASO did not reduce 
the Scn8a transcript (Figure 1C), while a dose-dependent reduction of Scn8a mRNA was obtained  
in mice treated with 15 to 45 µg of Scn8a ASO (Figure 1C).   Spinal cord Scn8a transcript was also 
reduced to 0.6 ± 0.1 relative to wildtype (n=5).  Treatment with 45 µg of ASO did not interfere 
with weight gain in the postnatal period, with no evidence of muscle wasting; at P21, body 
weight was 9.7 ± 1.4 g in untreated WT mice (mean ± SD, n=21) and 10.6 ± 1.2 (n= 18) in mice 
treated with 45 ug of ASO at P2 (p=0.2, unpaired t-test).   
 The therapeutic effect of the ASO was evaluated in mice expressing a conditional allele of 
Scn8a-p.Arg1872Trp (10).  Homozygous conditional mice were crossed with mice expressing the 
global EIIA-Cre transgene to activate the conditional allele.  The resulting (untreated)   
Scn8acond/+,EIIA-Cre offspring exhibited sudden onset of convulsive seizures at P14-P16, followed 
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by death within 24 hours (10).  Prior to seizure onset, these mice develop normally and do not 
exhibit epileptiform EEG discharges (10).  
  ASO was administered by ICV injection at P2 to litters containing 50% affected 
Scn8acond/+,EIIA-Cre mice and 50% unaffected Scn8acond/+ controls lacking Cre.   Treatment of 
Scn8acond/+,EIIA-Cre mice with control ASO did not prevent seizure onset and death at P14-P16  
(Figure 2A).  Administration of 15 µg to 45 µg of Scn8a ASO resulted in a dose-dependent 
increase in survival up to 7 weeks of age (Figure 2A, B).  To test the efficacy of repeated doses of 
ASO, mice were treated with 30 µg of ASO on P2 followed by a second dose of 100 µg on 
postnatal day 30, administered by stereotactic injection.   The second treatment further 
increased median survival from 6 weeks for 30 µg ASO to approximately 9 weeks (Figure 2A), 
indicating that repeated ASO administration might be effective as a long-term treatment, as is the 
case for spinal muscular  atrophy (16).  
 In mice treated with 45 µg ASO on P2, seizure onset begins at 6 weeks of age (Figure 2A).  
To determine the duration of the effect of ASO treatment on transcript level, and the relationship 
between transcript level and seizure onset, we measured Scn8a transcripts at three time points 
after treatment at P2 with 45 µg ASO (Figure 2D).  Transcript levels in treated mice at each point 
were compared with age-matched untreated wildtype controls.  The level of transcript at 3 
weeks of age was 50% of control (Figure 2D, also shown in Figure 1C).  At 5 weeks post 
treatment, Scn8a transcript level was increased to 80% of control, but no seizures were observed 
(Figure 2D).  At the time of seizure onset, transcripts in the mice with seizures had reached 
100% of the level of untreated controls.  Thus the reduction of Scn8a transcripts by ASO 
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treatment persists for approximately 6 weeks and is correlated with seizure protection.  The 
reduction of Nav1.6 protein at 3 weeks post treatment is demonstrated in Figure 2E.   
 To investigate the possibility that treated mice experience sub-threshold electrographic 
seizures during the period before seizure onset, mice were injected with 45 µg of ASO at P2 and 
monitored by EEG recording continuously for eight days, from P31 to P39.  Five of the six treated 
mice exhibited normal EEGs throughout this period, which ended near the age of seizure onset 
(Figure 3).   One treated mouse developed a convulsive seizure at the age of 37 days, followed 
within 30 seconds by death.  The EEG recording of this seizure (Figure 3) is similar to that 
previously reported for untreated mutant mice at P14-16 (10).  Thus treatment with SCN8A ASO 
delayed seizure onset but did not prevent the very rapid progression from initial seizure to death 
that is characteristic of mice expressing the R1872W mutation.   
 Since SCN8A is an essential gene (17), it was important to evaluate potential adverse 
effects of ASO treatment.  From previous work in the mouse we know that reduction of brain 
transcripts below 5% of the wildtype level is lethal (17,18) and reduction to 10% of wildtype 
level results in dystonia, muscle wasting and reduced body weight (17-19).  In contrast, 
reduction to 50% of wildtype level is well tolerated in the mouse, with only mild behavioral 
abnormalities (20).  Similarly, many haploinsufficient patients with 50% of wildtype expression 
have mild intellectual disability (21, 22).  These earlier observations predicted that the ASO 
treatment that prevented seizures, with approximately 50% of wildtype expression remaining in 
brain (Figure 1), would have only small effects on movement.  
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 To detect potential impairment of motor function, we compared ASO-treated mutant mice 
with untreated wildtype littermates.  We examined motor activity during the period of extended 
survival after ASO treatment.   In the open field test, mice treated with 45 µg of ASO exhibited 
normal activity at 6 weeks of age.  Total distance travelled, % time spent in the center of the open 
field, and number of rearing events did not differ from wildtype controls (Figure 4A).    
 In the wheel running test, the ASO treated mutant mice were slower than the wildtype 
mice (Figure 4B).  There was no difference between the two groups in the time spent running, 
but the distance covered was reduced by approximately one third, due to a slower average speed 
of 1.2 km/h for treated mutant mice compared with 2.0 km/h for wildtype controls.  Cerebellar 
function was assessed by analysis of ledge-walking, hind limb clasping, gait and kyphosis (23).  
The only deficit observed was impaired ledge-walking in 3 of the 5 treated mutant mice (Figure 
4C-F, Figure 2C).  The normal posture and home cage activity of ASO treated mice is 
demonstrated in Figure 2C and Supplemental Videos 1-3.   Thus reduction of Scn8a transcript to 
a level sufficient for delay of seizure onset results in only minor effects on movement.  Overall, 
the ASO treated mice remained alert and active until the onset of seizures.   
 Since Nav1.6 is a major determinant of the firing properties of excitatory neurons, 
reduction of Scn8a expression could have a general ameliorating effect on seizure disorders of 
various causes (24). To test this possibility, we examined the effect of the Scn8a ASO in a mouse 
model of Dravet Syndrome (DS), a DEE caused by loss-of-function mutations of SCN1A.   
Reduction of Scn8a by other methods was previously shown to be protective against acutely  
induced seizures in a Dravet mouse (25, 26).   We used the Kearney mouse model of DS that is 
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haploinsufficient due to deletion of exon 1 of Scn1a (27).  The untreated DS mice exhibited onset 
of spontaneous seizures by 4 weeks of age and 50% penetrance of seizures and lethality (Figure 
6A), consistent with previous reports (27).  In contrast, DS mice treated with a single dose of 45 
µg of Scn8a ASO on P2 survived beyond 5 months of age without behavioral seizures (Figure 5A).   
The Scn8a ASO resulted in 50% reduction of Scn8a transcript in brain and spinal cord of DS mice 
with no effect on the Scn1a transcript (Figure 5B).    Five consecutive days of EEG recordings of 
ASO treated DS mice recorded at 5 months of age did not detect any sub-threshold electrographic 
abnormalities or seizures (Figure 5C).  This extended period of protection after a single 
treatment suggests that ASO administration during a critical period of postnatal development 
might give long term seizure control in Dravet patients.  A transient developmental window of 
interneuron dysfunction has been described in Dravet mice (32).  Expansion of future testing of 
the Scn8a ASO to other seizure models will be of great interest. 
 
DISCUSSION 
 The experiments described here provide the first preclinical evidence that therapeutic 
reduction of Scn8a transcript could delay the onset of spontaneous convulsive seizures in 
patients with SCN8A encephalopathy.  ASO treatment did not result in major adverse effects, 
suggesting that it may be well tolerated in patients with SCN8A encephalopathy or Dravet 
Syndrome.  Further investigations will be required to determine whether initiation of ASO 
treatment after seizure onset is effective.  In these animal models, death follows within minutes 
to days of the first seizure; the resulting inability to evaluate post-onset treatment is a limitation 
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of the present study.  Clinical application will also require definition of a therapeutic window in 
human to prevent the deleterious effects of more extensive reduction of SCN8A expression.  Our 
observations on the Dravet Syndrome mouse support the exciting possibility that treatment with 
SCN8A ASO could be protective in Dravet Syndrome and in other seizure disorders with a variety 
of underlying etiology.  
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Figure 1. Scn8a ASO treatment reduces the abundance of Scn8a transcript in wildtype  
neurons and brain.  (A) Cartoon of the 3' end of the Scn8a gene.  The last two exons are 
represented by boxes separated by a line representing the last intron.  Coding sequences within 
the exons are shaded.  The position of the stop codon that terminates translation is marked as 
'stop'.  The sequence of the 20 bp Scn8a ASO is shown.  The ASO sequence is identical to the 
genomic sequence of the 3'UTR at a position approximately 500 bp downstream from the 
translation stop codon within the last exon of the gene. (B)  Primary cortical neurons from E14 
embryos of strain C57BL/6J were cultured for 3 days with the indicated concentration of Scn8a 
ASO.   (C)  The indicated dose of ASO was administered to C57BL/6J mice on postnatal day 2 and 
the abundance of Scn8a transcript in brain RNA was measured at P21. Five or six animals were 
treated with each dose; each symbol represents data from one animal.   
 
Figure 2.  Scn8a ASO delays seizure onset and prolongs survival of mutant mice expressing 
the pathogenic mutation SCN8A-R1872W.  (A)  Scn8acond/+, EIIA-CRE mice were treated on 
postnatal day 2 by ICV injection with the indicated mount of control or Scn8a ASO.  A second 
dose of 100 µg of Scn8a ASO at P35 further extended survival (p<0.001) (dotted line).  (B) Dose-
dependence of mean survival; values are mean +/- SEM.  (C)  Scn8acond/+, EIIA-CRE mice treated 
with 45 ug exhibit normal posture without hind limb clasping.  (D) Duration of the effect of 
Scn8a ASO on transcript level.  Brain RNA was prepared from Scn8acond/+, EIIA-CRE mice treated 
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with 45 µg of ASO and untreated age-matched wildtype mice and analyzed by qRT-PCR.  (E) 
Reduction of Nav1.6 protein in brain at 3 weeks of age in mice treated with 45 µg of ASO as in (D).   
 
Figure 3.  ASO treatment protects against electrographic seizures.  Mutant mice of genotype 
Scn8acond/+,EIIA Cre were treated with 45 µg Scn8a ASO by ICV at P2 and monitored from the age 
of P31 to P39 by 24 hour video EEG recording.  Traces recorded from right and left cortical 
electrodes of six mice are shown.  Five mice were completely protected from electrographic and 
behavioral seizures.  Mouse #2 exhibited a single, fatal, generalized tonic-clonic seizure at P37 
that closely resembled the EEG profile in untreated mutants at P15 (10).  (P37 corresponds to 
the age of the earliest seizure in the cohort of 10 mice treated with 45 ug of ASO in Figure 2.)  
 
Figure 4.   Motor activity of ASO treated mice.  Scn8acond/+,EIIA Cre mice were treated with 45 
µg Scn8a ASO at P2.   A)  Activity in an open field was monitored for 30 min at 45 days of age.  
Treated mutant mice did not differ significantly from wildtype mice in average running speed 
(Student's t test, p=0.12) or percent of time spent in the center of the open field (Two-way 
Anova, p=0.83).  Rearing behavior of mutant and wildtype mice was also comparable.   
B) Wheel running activity was monitored 24 hours/day during the 4 day interval between P31 
and P39, after habituation to the running cage for 10 days.  The distance travelled by the treated 
mutant mice during the 96 hours of monitoring was significantly smaller than for wildtype mice.  
There was no significant difference in the time spent running, but the average speed was lower 
for the mutant mice.  C-F)  Cerebellar function was assessed at 5 weeks of age by analysis of 
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ledge-walking, hind limb clasping, gait and kyphosis as described (23). The only deficit observed 
was impaired ledge-walking in 3 of the 5 treated mutant mice.   Each symbol represents one 
animal and values are the mean of triplicate assays.  WT, wildtype C57BL/6J mice untreated with 
ASO;  Mutant, Scn8acond/+,EIIA Cre mice treated with 45 µg ASO;  
p values are for the comparisons between WT and mutant mice (Student's t-test).  
 
Figure 5.  Scn8a ASO rescues survival of Dravet Syndrome mice.  Scn1a+/- mice were treated 
on P2 with 45 µg Scn8a ASO.   (A) For untreated Scn1a+/- mice, median survival was 26 days with 
50% penetrance of the lethal phenotype, consistent with the original description of this Dravet 
model (27).  In contrast, all of the ASO treated mice have survived beyond 5 months of age 
(p=0.004, Mantel-Cox Log-rank test).   Tick marks represent living mice. (B) The Scn8a ASO 
reduces Scn8a transcript level with no effect on Scn1a transcript level. Brain RNA was prepared 
from untreated wild-type P21 (solid symbols) or mice treated with 45 ug Scn8a ASO (open 
symbols).  (C) The Scn8a ASO protects against electrographic seizures in Scn1a+/- mice.   Four 
ASO treated mice, 5 months of age, were monitored for 5 successive days with 24-hour EEG 
recording.  No electrographic seizures or other EEG abnormalities were observed.  Two traces 
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Supplemental videos.  Scn8a cond/+, EIIA-Cre mice were treated on P2 with 30 µg of Scn8a ASO 
and assessed at P21, one week beyond the survival without ASO.    
Video 1.  Normal gait and movement, side view.  30 sec.   
Video 2.  Normal gait and activity, overhead view.    
Video 3.  Absence of hind-limb clasping in the treated mutant mice.  
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